Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCRT Followed by NALIRIXELOX and Sintilimab as Total Neoadjuvant Therapy in High-Risk Locally Advanced Rectal Cancer
NCT07474103Recruiting
- Start
- Nov 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules, Lipid-based Nanoparticles, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of sintilimab and nanoliposomal irinotecan in rectal cancer. Primary endpoint: Complete Response Rate at 6 months. Started Nov 2025; status: recruiting.
02
Drugs
sintilimabnanoliposomal irinotecan
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07474103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07474103.